Resources

BIA welcomed the focus on life sciences SMEs, engineering biology, and the measures designed to help high-growth companies scale and remain rooted in the UK.

A major funding boost, support for scale-ups, and regulatory reform—this week’s update explores how the Government’s new Industrial Strategy backs our sector. Plus, Draig Therapeutics launches with $140 million, the UK shines at BIO in Boston, and Syncona sets its sights on future growth.

The policy landscape for deep biotech has seen remarkable strides over the past year, positioning the UK as a leader in engineering biology innovation.

The BioIndustry Association (BIA) has today published a report highlighting the rapid growth of the UK’s Deep Biotech sector.

In a world of uncertainty, Britain’s biotech future looks strong.

In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at BIA, explores a major milestone for agricultural innovation in England: the implementation of a clear, science-based regulatory pathway for precision-bred plants.

Last week was a big one for UK life sciences, from the BIA Committee Summit shaping our sector’s future to major leadership changes at UKRI and NHS England. In this week’s update, I explore what these developments mean for our industry, alongside breakthroughs in AI, investment, and accessibility in healthcare.

As 2024 comes to a close, we’re proud to reflect on a year of championing the life sciences sector, from driving impactful policy changes to fostering connections across the UK and beyond. Dive into our key achievements, events, and milestones that shaped the year and set the stage for an exciting 2025.

Imperial, the leading global science university, is achieving a major step up in its life sciences capacity at its White City Deep Tech Campus through a major new joint venture with Bruntwood SciTech.

Read today's blog to learn about our latest reports, upcoming events and our CEO's thoughts on the upcoming budget.

In this blog, Izzy Webb outlines why the UK has published voluntary guidance to promote DNA synthesis and who the guidance is intended for.

Steve Bates OBE, CEO of the BIA, responded to the announcement of a new Regulatory Innovation Office.

The BIA’s policy and public affairs team attended the conferences of the three major UK parties this year. This is a key point in the political calendar and allows us to highlight the sector through fringe events, meet policymakers, and get a sense of the political environment.

Financing led by Ahren, OMX Ventures and Paladin Capital Group represents one of the largest UK biotech Series A rounds in recent years.